ArticleChembiochem : a European journal of chemical biology2026
Monoclonal Antibodies Accessing the Cytosol of Living Cells and Binding to Polo-Like Kinase 1 Interdomain Linker Affect Mitotic Behavior.
Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Polo-like kinase 1 (PLK1) is a master regulator of mitosis and a well-established driver of cancer progression. Strategies to target PLK1 have largely focused on RNA interference using small interfering RNAs or small-molecule inhibitors. Here, we introduce the direct intracellular targeting of the PLK1 interdomain linking the polo-box domain to the kinase domain using monoclonal antibodies. Three monoclonal antibodies recognizing the interdomain region were delivered into the cytosol of HeLa cells by electroporation. These antibodies were shown to bind PLK1 in living cells and to modulate mechanisms involved in mitotic progression. Our results establish these antibodies as tools to probe PLK1 function through real-time labeling and interference with the mitotic machinery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.